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Abstract
Background & Aims—Dysregulated Ca2+ homeostasis likely contributes to the etiology of
IBD-associated loss of bone mineral density (BMD). Experimental colitis leads to decreased
expression of Klotho, a protein which supports renal Ca2+ reabsorption by stabilizing TRPV5
channel on the apical membrane of distal tubule epithelial cells.
Methods—Colitis was induced in mice via administration of 2,4,6-trinitrobenzenesulfonic acid
(TNBS) or transfer of CD4+IL10−/− and CD4+, CD45RBhi T cells. We investigated changes in
bone metabolism, renal processing of Ca2+, and expression of TRPV5.
Results—Mice with colitis had normal serum levels of Ca2+ and parathormone. Computed
tomography analysis demonstrated decreased density of cortical and trabecular bone, and there
was biochemical evidence for reduced bone formation and increased bone resorption. Increased
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fractional urinary excretion of Ca2+ was accompanied by reduced levels of TRPV5 protein in
distal convoluted tubules, with a concomitant increase in TRPV5 sialylation. In mIMCD3 cells
transduced with TRPV5 adenovirus, the inflammatory cytokines tumor necrosis factor (TNF),
interferon (IFN)γ, and interleukin 1β reduced levels of TRPV5 on the cell surface, leading to its
degradation. Cytomix induced interaction between TRPV5 and UBR4, an E3 ubiquitin ligase;
knockdown of UBR4 with small interfering RNAs prevented cytomix-induced degradation of
TRPV5. The effects of cytokines on TRPV5 were not observed in cells stably transfected with
membrane-bound Klotho; TRPV5 expression was preserved when colitis was induced with TNBS
in transgenic mice that overexpress Klotho or in mice with T-cell transfer colitis injected with
soluble recombinant Klotho.
Conclusion—Following induction of colitis in mice via TNBS administration or T-cell transfer,
TNF and IFNγ reduce expression and activity of Klotho, which would otherwise protect TRPV5
from hyper-sialylation and cytokine-induced TRPV5 endocytosis, UBR4-dependent
ubiquitination, degradation, and urinary wasting of Ca2+.
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INTRODUCTION
Loss of BMD is one of the more common extra-intestinal symptoms of Inflammatory Bowel
Diseases (IBD). The relative risk of fracture in IBD patients has been estimated to be 40%
higher than in general population, with the prevalence of osteopenia and osteoporosis
varying significantly depending on the study populations, geographic location and study
design, and fall within the range of 22%–77% for osteopenia and 17%–41% for
osteoporosis1. There are many risk factors predisposing for the loss of BMD in IBD patient
population, as we reviewed earlier2. One of the potential mechanisms contributing to the
IBD-associated bone loss is impaired mineral homeostasis, renal and intestinal Ca2+
(re)absorption in particular. Malnutrition together vitamin D insufficiency/deficiency are
considered as important factors in the pathogenesis of bone loss in IBD. It is also plausible
that decreased expression and activity of key Ca2+ transport proteins in the gut and kidney,
induced by inflammatory mediators, may be the underlying cause of the reported failures of
dietary Ca2+ and vitamin D supplementation in IBD3, 4. Indeed, in mouse model of Crohn’s-
like ileitis (TNF-overexpressing TNFΔARE mice), both duodenal and renal Ca2+ absorptive
epithelia displayed significant down-regulation of TRPV6, calbindin D9K, plasma
membrane Ca2+ ATPase (PMCA1b), as well as calbindin D28k, and Na+/Ca2+ exchanger
(NCX1), respectively5. In this report, changes in expression of these Ca2+ transport genes
were accompanied with increased bone resorption, as documented by tomography scanning
and increased total deoxypyridinoline in serum of the TNFΔARE mice. Although bone
density in IBD patients poorly correlates with cumulative steroid exposure, steroids certainly
contribute to the pathogenesis of osteopenia and osteoporosis. One likely mechanism was
described by Huybers et al.6, who demonstrated that in mice oral methylprednisolone
significantly decreases duodenal Ca2+ absorption. Similar to TNFΔARE, this decrease
coincided with decreased TRPV6 and calbindin D9k mRNA and protein expression, with
unaltered serum Ca2+ or 1,25(OH)2D3 levels6.
In 1970, Joseph Kirsner’s group demonstrated elevated urinary Ca2+ excretion in patients
with ulcerative colitis and with granulomatous regional enteritis7. However, this observation
or the involved molecular mechanisms were not investigated further in IBD or in animal
models. Under physiological conditions, the primary site of active renal Ca2+ reabsorption is
the epithelium of the distal convoluted tubules, and is mediated via apical selective
nonvoltage-gated Ca2+ channel, TRPV5. TRPV5−/− mice show robust renal Ca2+ wasting
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and reduced bone thickness despite the compensatory intestinal Ca2+ hyperabsorption
accompanied by enhanced duodenal TRPV6 expression8. TRPV5 is regulated by
transcriptional mechanisms (calciotropic hormones including 1,25(OH)2 vitamin D3,
parathormone (PTH), and estrogens), by pH- and Ca2+-dependent regulatory mechanisms,
trafficking of TRPV5 to the luminal membrane and by physical interactions with associated
proteins9. It is also controlled by renal Klotho, a multifunctional protein which regulates Pi/
Ca2+ metabolism as well as aging10. Klotho has been directly implicated in the regulation of
transepithelial Ca2+ transport through regulation of both apical entry as well as basolateral
Ca2+ exit. Through its glucuronidase activity, Klotho modulates N-glycosylation of TRPV5
at Asn358 by removal of the capping sialic acid, which enables physical interaction of
galectin 1 with TRPV5 on the cell surface and promotes its apical retention and
activity 11, 12. Indeed Klotho has been demonstrated to prevent renal Ca2+ loss13.
Interestingly, we have demonstrated profound effects of experimental colitis and the
associated cytokines (TNF and IFNγ) on renal Klotho expression14, 15, thus suggesting that
this may translate into defective function of TRPV5 and impaired renal Ca2+ handling in
experimental colitis. We propose a scenario whereby during colitis, TNFα and IFNγ act to
decrease Klotho expression and activity, which would otherwise protect TRPV5 from hyper-
sialylation, and from cytokine-induced TRPV5 endocytosis, UBR4-dependent
ubiquitination, degradation, and urinary Ca2+ wasting.
METHODS
Mice
All animal procedures were approved by the Institutional Animal Care and Use Committee
at the University of Arizona. Wild type, Rag1−/− and IL10−/− mice (C57BL/6J background)
were purchased from the Jackson Laboratory and maintained under speci c-pathogen-free
conditions. TRPV5-eGFP transgenic mice, which express eGFP in the epithelium of the late
distal convoluted tubules (DCT2), the connecting tubule (CNT), and the initial part of the
cortical collecting duct (iCCD)16, were generously provided by Drs. Jeppe Praetorius and
Marlene Vind Hofmeister from the Aarhus University, Denmark. EFmKL46 are transgenic
mice overexpressing Klotho under the control of the human elongation factor EF-1α
promoter on 129S1/SvImJ background17.
Cells, Cytokines, Klotho plasmids, and TRPV5 adenoviral construct
mIMCD3 and MDCK cells, plasmids and adenoviral gene delivery are described in detail in
the supplemental Methods section. As cytomix, 100 U/ml of IFNγ, 10 ng/ml of TNFα and 2
ng/ml of IL1β were used throughout the study.
Experimental colitis
Detailed description of models, including acute TNBS colitis, chronic adoptive T-cell
transfer colitis (CD4+ T cells isolated from IL-10−/− mice transferred into Rag1−/− mice and
synchronized with dietary piroxicam) and CD4CD45RBhi-T-Cell transfer model (transferred
Rag−/− mice with CD4CD45RBhi naïve T cells sorted from WT spleens) is provided in the
Supplemental Methods section.
Real-Time RT-PCR, cytokine and bone turnover analysis
Detailed description of real-time RT-PCR analysis of colonic cytokine expression and the
analysis of serum cytokine and bone turnover markers is provided in Supplemental Methods
section.
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μCT evaluation of cortical and trabecular bone density
Detailed description of the μCT analysis of mouse femurs is provided in Supplemental
Methods section.
Fractional urinary Ca2+ excretion
Plasma (P) and urine (U) creatinine (Cr) and Ca2+ were analyzed by commercial assays
(Abcam, Cambridge, MA; and BioVision, Milpitas, CA, respectively) from samples
harvested at the time of sacrifice. Fractional excretion of Ca2+ (FECa2+) was calculated
according to the following formula:
In vitro Ca2+ uptake
Detailed description of in vitro Ca2+ uptake assay18 in mIMCD3 cells as well as in primary
renal tubular cells is provided in Supplemental Methods section.
Isolation of TRPV5-expressing GFP+ renal epithelial cells from TRPV5-eGFP transgenic
mice
The use of TRPV5-eGFP transgenic reporter mice16 for renal tubule isolation is described in
more detail in the Supplemental Methods section.
Cell surface biotinylation, immunoprecipitation, and western blotting
Detailed description of the cell surface biotinylation, immunoprecipitation, and western blot
analyses is provided in Supplemental Methods section.
Immunofluorescence
Detailed description of the protocol used for immunostaining of renal TRPV5 is provided in
Supplemental Methods section. Specificity of TRPV5 antibody was verified by
immunostaining of adjacent section using mouse monoclonal antibody against distal-
convoluted tubule-specific thiazide-sensitive NaCl co-transporter (Millipore, Billerica, MA;
data not shown).
TRPV5 sialylation
Detailed description of the methods used for detection of TRPV5 sialylation in the kidneys
of control and colitis mice is provided in Supplemental Methods section. Since colitis results
in decreased abundance of total TRPV5, for better visualization, sample loading was
adjusted based on TRPV5 densitometric analysis to show equal amount of TRPV5.
Tandem mass spectrometry coupled to liquid chromatography (LC-MS/MS) and siRNA
knockdown of UBR4
Detailed description the proteomic analysis leading to identification of UBR4 ubiquitin
ligase as a TRPV5 binding partner in cymomix-treated distal convoluted tubule cells as well
as siRNA-mediated knockdown of UBR4 is provided in Supplemental Methods section.
Statistical Analysis
Statistical significance was determined by Student t-test or analysis of variance (ANOVA)
followed by Fisher PLSD post-hoc test, as appropriate, using SigmaPlot 12 software
package (Systat; Chicago, IL). Data are expressed as mean ± standard error of mean (SEM).
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Development of colitis in TNBS and adoptive T-cell transfer models
TNBS colitis represents a well-characterized model of acute colitis in response to an
epithelial injury and a haptenizing agent19. Adoptive transfer of CD4+ T cells from IL-10
deficient mice into syngeneic recipients lacking T and B cells and synchronized by dietary
exposure to piroxicam induces moderate to severe colitis within 6–8 weeks with symptoms
resembling human IBD20. The CD4CD45RBhi-T-Cell transfer model, is also well-
characterized model of chronic colitis and induces both colitis and small bowel
inflammation, making this a model similar to Crohn’s disease21.
Development of robust colitis at the end of the study was confirmed by progressive loss of
body weight and colonic histology (Fig. 1A, B) as well as colonic expression of TNF, IFNγ,
IL17, and IL-1β mRNA (Suppl. Fig. S1).
Decreased bone mineral density in TNBS and adoptive T-cell transfer colitis
Decreased serum concentration of osteocalcin (more significant in TNBS colitis) and
significant increase of serum tDPD suggested a defect in bone remodeling with decreased
bone formation, and increased bone resorption, respectively (Fig. 2A, B). Surprisingly,
serum levels of RANKL were significantly decreased in both models of colitis (Fig. S2),
thus suggesting that in these two models, RANKL does not play a significant role in the
pathogenesis of bone loss or that its circulating levels are not reliable markers of bone
resorption. Serum levels of TNF were increased in both models, albeit to a greater extent in
acute TNBS colitis, while circulating IL-6 was only elevated in TNBS-treated mice (Suppl.
Fig. S2). μCT analysis of mouse femurs indicated significant loss of both cortical and
trabecular bone in both disease models. This loss of bone mineral density is exemplified by
the representative 3D reconstruction images of cortical and trabecular bone in Fig. 2C, D
and in the detailed morphometric analyses presented in Suppl. Fig. S3 and S4.
Impaired renal Ca2+ reabsorption and decreased expression of TRPV5 and KLOTHO in
renal distal convoluted tubules in experimental colitis
We measured fractional urinary Ca2+ excretion (FECa2+) based on serum and urine
concentration of creatinine and Ca2+ at the time of sacrifice. In both models of colitis,
FECa2+ increased significantly compared to healthy controls (Fig. 3A, B, left panels). We
analyzed the expression of cell surface and total TRPV5 and total KLOTHO protein
expression in GFP+ renal epithelial cells isolated from control and TNBS-treated TRPV5-
eGFP reporter mice. TRPV5 surface and total protein expression was decreased in parallel
with decreased KLOTHO (the latter as previously reported14 (Fig. 3A, middle and right
panels). Similar decrease of total TRPV5 and KLOTHO protein expression was observed
using total kidney cortex lysate from naïve Rag1−/− mice with T-cell transfer colitis (Fig.
3B, middle and right panels). Immunofluorescence analysis of TRPV5 protein in the distal
convoluted tubules in both models of colitis confirmed these results (Fig. 3C).
Decreased Ca2+ uptake and TRPV5 expression in cytokine-treated renal epithelial cells in
vitro
Mouse renal intermedullary collecting duct epithelial cells (mIMCD3), which normally do
not express TRPV5 or KLOTHO were stably transfected with an empty vector or with
plasmid coding for V5-KLOTHO, followed by transduction with adenovirus encoding
human TRPV5 and were treated with cytomix for 48 hours. 45Ca2+ uptake of was performed
with background subtraction from cells transduced with non-coding (empty) adenovirus.
Consistent with the fractional excretion data, inflammatory cytokines commonly associated
with IBD led to significantly reduced TRPV5-dependent Ca2+ uptake in mIMCD3 cells not
Radhakrishnan et al. Page 5













expressing KLOTHO (Fig. 4A). However, cytomix was not effective in cells stably
transfected with KLOTHO (Fig. 4A, B). Cytomix also significantly inhibited Ca2+ uptake in
isolated primary renal epithelial cells (Suppl. Fig. S5A). Combinations of TNF+IL1β or
IFNγ+IL1β were the most effective in reducing the abundance of cell surface TRPV5 in
primary renal epithelia (Suppl. Fig. S5B). Short (4 hr) exposure of isolated GFP+ epithelial
cells from TRPV5-eGFP mice to cytomix resulted in decreased expression of TRPV5 at the
cell surface but not of the total cellular TRPV5, thus suggesting endocytosis as preceding
intracellular degradation in response to inflammatory cytokines (Fig. 4C). Longer exposures
of the primary epithelial cells could not be performed due to decreasing cell viability in
culture.
Soluble KLOTHO partially prevents the cytokine-induced loss of TRPV5 in vitro and in vivo
KLOTHO participates in specific removal of α2,6-linked sialic acids and regulates cell
surface retention of TRPV5 through this activity by facilitating interaction of desialylated
TRPV5 with galectin-112. Since we demonstrated that renal expression of KLOTHO is
decreased in colitis (Fig. 3A, B and ref.14), we investigated the degree of sialylation of
TRPV5 by immunoprecipitating the protein from control and TNBS-treated WT mice, and
probing with biotinylated sialic acid-specific SNA lectin. Fig. 5A demonstrates
representative image depicting higher degree of sialylation of TRPV5 in colitic mice. Since
KLOTHO protein is expressed in both membrane bound and soluble form, we tested if
recombinant soluble KLOTHO would be capable of reducing the effects of cytomix on
TRPV5 endocytosis in vitro. Indeed, such effect could be observed in both MDCK and
mIMCD3 cells transduced with ad-hTRPV5 (Fig. 5B). To further confirm this observation,
we induced colitis in WT or EFmKL46, which are transgenic mice overexpressing Klotho
gene under the control of the human elongation factor EF-1α promoter17. EFmKL46 mice
overexpress KLOTHO in extrarenal tissues only, therefore any potential effect in the kidney
would be the result of soluble KLOTHO. Overexpression of KLOTHO did not affect the
development or severity of colitis in EFmKL46 mice (data not shown). However, the
reduction in total renal TRPV5 expression was much less pronounced in colitic EFmKL46
mice, thus suggesting at least partial protection of TRPV5 by soluble KLOTHO in
experimental colitis (Fig. 5C). In the chronic and progressive model of adoptive transfer of
CD4+CD45RBHi naïve T-cell into Rag1−/− recipients, mice were 6 weeks post-transfer with
PBS or 2μg of recombinant KLOTHO i.p. daily for 7 days. KLOTHO injection did not
change the course of disease (data not shown). However, TRPV5 protein level in the
kidneys was restored in KLOTHO-injected mice (Fig 5D and Fig 5E). Consistently, we
observed normalization of urinary fractional Ca2+ excretion in colitic mice administered
recombinant soluble KLOTHO (Fig 5F).
Membrane-bound KLOTHO prevents cytokine-induced ubiquitination, loss of cell-surface
and total TRPV5 protein expression
Although ubiquitination of TRPV5 has not been previously described, it is a common
phenomenon among internalized membrane proteins targeted for degradation. Such
mechanism has been recently demonstrated for a close member of the TRPV family;
TRPV6, which is ubiquitinated by an archetypal HECT ubiquitin E3 ligase, Nedd4-222.
TRPV5 immunoprecipitated from cytomix-treated mIMCD3 cells showed characteristic
laddering pattern when reacted with anti-ubiquitin antibody, which increased in intensity
between 4 and 8 hours of treatment (Fig. 6A). This was paralleled by decreased cell surface
expression of TRPV5, which preceded decreased total TRPV5 abundance at 8 hours (Fig.
6A). Intriguingly, ubiquitination and loss of TRPV5 protein was not observed in cytomix-
treated mKL-mIMCD3 cells, which expressed KLOTHO. Cytomix did not impair physical
interaction of KLOTHO with TRPV5 in mKL-mIMCD3 cells (Fig. 6B).
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Ubiquitination by UBR4 E3 ubiquitin ligase leads to proteasomal degradation of TRPV5 in
response to inflammatory cytokines
Mass spectrometric analysis of co-immunoprecipitated proteins interacting with HA-tagged
TRPV5 in mIMCD3 cells treated with cytomix identified multiple proteins among which
only one had known ubiquitin ligase activity; UBR4/p600 a relatively well-characterized
ubiquitin E3 ligase23 (Fig. 7A). Colitis did not affect renal expression of UBR4/p600 mRNA
(Suppl. Fig. S6). Transfection of mIMCD3 cells with UBR4 siRNA effectively knocked-
down expression of UBR4 mRNA and protein (Fig. 7B). Due to the size of UBR4 (ca.
600kDa) and technical difficulties with PAGE resolution and transfer, dot blot was utilized
instead of traditional Western blotting. mIMCD3 cells transfected with non-silencing siRNA
or UBR4 siRNA were transduced with Ad-hTRPV5 and treated with the cytomix for 8
hours. Consistent with data presented in Fig. 6, cytomix treatment led to ubiquitination of
TRPV5 in cells transfected with non-silencing siRNA; however, dramatically decreased
TRPV5 ubiquitination was observed in cells transfected with UBR4-specific siRNA (Fig.
7C). UBR4 knock-down also led do increased baseline expression of TRPV5 and prevented
cytomix-induced loss of TRPV5 protein expression (Fig. 7D). Since adenoviral transduction
combined with cytokine and proteasome inhibitor treatment resulted in increased cell death,
we used stably transfected and flow-sorted mIMCD3 cells expressing GFP-TRPV5 fusion
protein. As expected, cytomix reduced expression of TRPV5, but both proteasome inhibitors
(MG-132 and clasto-lactacystin β-lactone) effectively eliminated this response indicating a
major role for proteasomal degradation pathway (Fig. 7E). Bafilomycin, an inhibitor of
lysosomal degradation, was only partially effective suggesting a contribution of lysosomal
degradation in the cytokine-induced loss of TRPV5 (Fig. 7E).
DISCUSSION
Osteopenia and osteoporosis are two of the more common extraintestinal symptoms with a
general consensus that IBD patients are at a significantly higher risk of developing
metabolic bone disease and low BMD than the healthy subjects. The relative risk of fracture
in IBD patients has been estimated to be 40% higher than in general population1. While
increased osteoclast and decreased osteoblast activity have been implicated in the net bone
loss in IBD, the exact molecular basis for reduced BMD has still not been established and is
likely multi-factorial. Likely risk factors predisposing to lower BMD in IBD patients include
malabsorption of vitamin D, Ca2+ and vitamin K, low body mass index, low bone mineral
intensity peak in IBD patients with pediatric onset, chronic inflammatory state, type of IBD
(CD vs. UC; small intestinal involvement), increasing age, female gender, decreased
mobility, and chronic use of corticosteroids. However, recent reports have shown that bone
loss occurs even before clinically significant bowel disease has occurred24 and in pediatric
patients, mild cortical bone loss was detected even at the time of diagnosis25.
Vitamin D insufficiency and deficiency in IBD has received much attention in recent years.
However, several studies have shown no relationship between BMD and measured serum
25(OH)D3 levels26,27. Moreover, studies have indicated that significant proportion of adult
and pediatric IBD patients have elevated levels of the bioactive metabolite, 1,25(OH)2D3,
which correlates with decreased BMD28, 29. Our group recently described that expression of
Klotho, a critical regulator of vitamin D3 metabolism and Ca2+ homeostasis is decreased in
several mouse IBD models14. Moreover, we recently demonstrated that high vitamin D3
supplementation during active colitis negatively impacts bone metabolism30. These findings
indicate a very complex effect of acute and chronic intestinal inflammation on systemic
Ca2+ homeostasis and bone turnover. In 1970, Breuer et al7 described elevated urinary Ca2+
excretion in patients with ulcerative colitis and granulomatous regional enteritis, an
observation confirmed later by Abreu et al28 in CD patients. Huybers et al5 showed that
TNFΔARE mice, which develop spontaneous ileitis, have reduced mRNA expression of
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duodenal apical TRPV6 Ca2+ channel, calbindin-D9k, and basolateral PMCA1b Ca2+ pump.
The same report highlighted changes in renal Ca2+ transporters NCX1 and calbindin-D28k,
although with no change in the expression of TRPV5 mRNA. It remained unclear whether
the described changes in renal key Ca2+ transporters at the transcript levels alone could
explain urinary Ca2+ losses in IBD patients.
Klotho can directly bind TRPV5 channel at the cell surface and regulate its function by
hydrolyzing terminal sialic acid residues of the glycan chains, which could in turn prevent
TRPV5 internalization and increase its abundance on the cell surface12. This observation
suggested that in the face of down-regulated renal Klotho expression in colitis14, changes in
TRPV5 protein rather than its transcript, may be critical in reducing Ca2+ reabsorption in the
distal convoluted tubules. In the present study, we employed two distinct models of acute
and chronic colitis associated with altered bone metabolism and decreased BMD based on
μCt analysis. Loss of BMD was paralleled with increased urinary Ca2+ excretion which
could be reproduced in vitro in cells treated with a combination of three prominent
mediators of intestinal inflammation. Inflammation-associated loss of TRPV5 protein
expression was associated with increased TRPV5 sialylation, which implicated the loss of
Klotho expression in this process. Indeed, overexpression of Klotho in vitro or in transgenic
EFmKL46 mice in vivo, prevented the negative effects of inflammatory cytokines on
TRPV5 protein and Ca2+ absorption. The latter model, in which extrarenal Klotho
expression is driven by the human elongation factor EF-1α promoter, suggests that soluble
Klotho may be sufficient in preventing the effects of inflammatory cytokines on TRPV5
protein, and opens a potential therapeutic avenue. This notion is further strengthened by our
observation that soluble recombinant Klotho prevented cytokine-induced loss of plasma
membrane TRPV5 and that physical association of TRPV5 and Klotho was not affected by
cytomix treatment in vitro.
In the current study, we also describe the fate of TRPV5 protein in response to inflammatory
cytokines during Klotho deficiency. Following hyper-sialylation, TRPV5 is internalized and
becomes targeted for degradation through the ubiquitin (Ub) system, a mechanism not
uncommon in response to cytokine stimulation31, 32. Recently, another TRP family member,
TRPV6, was shown to be a target of at least one Ub E3 ligase, Nedd4-222. Here, we have
identified UBR4, an E3 Ub ligase, as a prominent binding partner of TRPV5 in renal
epithelial cells exposed to cytomix. UBR4 has been shown to have E3 ligase activity and it
recognizes and binds to proteins bearing specific N-terminal residues that are destabilizing
according to the N-end rule. This binding subsequently leads to ubiquitination and
degradation of the target protein23. A comprehensive study by Nakatani et al.33 showed that
UBR4/p600 localizes in continuous mesh patterns from the nucleus to the cytoplasm and
that it perforates the nuclear envelope. Based on their findings, the group also concluded that
p600 concentrates at the leading edge of membrane structures. They also described that
p600 and clathrin form an integrated structure near the leading edge. Clathrin is known to
play an important role in transporting membrane domains between intracellular membrane-
bound compartments (including the endosomes) by forming clathrin-coated membrane
vesicles34 and Nakatani et al.33 postulated that UBR4/p600 is an essential structural
component for membrane morphogenesis. Although it is tempting to speculate that UBR4
may be playing a direct role in the internalization of TRPV5 followed by ubiquitination, at
present, we don’t have the evidence to support this theory. At this point, we hypothesize that
the loss of Klotho leads to accumulation of sialylated TRPV5 at the plasma membrane,
which creates permissive conditions for the proinflammatory cytokines to trigger
endocytosis (or to synergize with intrinsic recycling mechanism) and proteasomal and to a
lesser degree lysosomal degradation of the Ca2+ channel. Whether UBR4-mediated
ubiquitination occurs before, during, or after TRPV5 internalization, or a combination of
those, will require additional studies. The end result of the process is decreased renal Ca2+
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reabsorption and urinary Ca2+ wasting. This mechanism, along with the previously
implicated changes in intestinal Ca2+ absorption, likely contributes to the systemic
imbalance of Ca2+ homeostasis and to IBD-associated loss of BMD (Fig. 7F). In addition to
describing this novel mechanism, our data points to a potential usefulness of recombinant
soluble Klotho as adjuvant therapy for osteopenia or osteoporosis in IBD. Hu et al.35
demonstrated that peripherally administered recombinant soluble Klotho can be identified in
the renal tubular lumen by electron immunomicroscopy and can be detected in urine
obtained with in vivo free-flow micropuncture. The same group demonstrated that in rats
injected i.p. with a single dose of soluble recombinant Klotho tagged with an IR dye, the
protein persisted in serum for 24 hours and could be detected in urine 20 min after injection
and kidneys retained the IR-labeled Klotho for up to two days36. Indeed, pre-clinical
efficacy of recombinant soluble Klotho has been recently demonstrated by Chen et al.37 who
showed that i.p. injection of soluble Klotho extended the life span of Klotho hypomorphic
mice, ameliorated premature aging-related phenotype, attenuated renal fibrosis, and reduced
cellular senescence.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Development of colitis in (A) TNBS and (B) CD4+IL−/− adoptive T-cell transfer models
Body weight changes are shown as percentages of the baseline value and are means ± SEM.
(A) Five days after TNBS treatment, haematoxylin and eosin (H&E)-stained colon tissue
sections were examined. (B) For T-cell transfer colitis, colon tissues were examined after 6
weeks post T-cell transfer. Data are representative of at least three independent experiments.
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Fig. 2. Altered bone metabolism and osteopenia in TNBS and CD4+IL−/− adoptive T-cell
transfer models
(A) Serum concentration of osteocalcin (bone formation marker) and (B) tDPD (bone
resorption marker); * p<0.05; t-test. (C and D) Representative μCT 3D-reconstruction of the
femoral midshaft, cortical and distal femoral metaphyseal trabecular bone of control and
colitic mice.
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Fig. 3. Decreased renal Ca2+ reabsorption in experimental colitis
(A) TNBS colitis; fractional urinary Ca2+ excretion (FECa2+) (left panel); cell surface and
total TRPV5, and KLOTHO expression in cortical epithelial cells of TNBS-treated TRPV5-
eGFP reporter mice (middle panel; eGFP used as a leading control demonstrating equal
contribution of TRPV5-expressing epithelial cells of DCT and connecting ducts); summary
of Western blot analysis of total TRPV5 protein expression in the renal cortex in TNBS
colitis (right panel; mean ± SD, *p<0.05; Student t-test). (B) CD4+IL10−/− adoptive T-cell
transfer model; fractional urinary Ca2+ excretion (FECa2+) (left panel); total expression of
TRPV5 and KLOTHO in the renal cortex (middle panel); summary of Western blot analysis
of total TRPV5 protein expression in the renal cortex in T-cell transfer colitis (right panel;
mean ± SD, *p<0.05; Student t-test). (C) Immunofluorescent staining of TRPV5 (red) of the
two models of colitis (nuclei counterstained in green).
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Fig. 4. Decreased Ca2+ uptake and TRPV5 expression in cytokine-treated renal epithelial cells in
vitro
(A) TRPV5-mediated 45Ca2+ uptake in cells stably transfected with empty vector
(mIMCD3) or membrane-bound Klotho (mKL-mIMCD3), transduced with Ad-HA-TRPV5
and treated with control medium or cytomix for 48 hours. * p<0.05 control mIMCD3 vs.
cytomix-treated mIMCD3, # p<0.05 cytomix-treated mIMCD3 vs. mKL-mIMCD3; (B)
Verification of KLOTHO expression in mIMDC3 cells stably transfected with pcDNA3.1/
V5-His-human KL plasmid which codes for full-length human Klotho cDNA. KLOTHO V5
epitope tag was detected by Western blotting. (C) Loss of cell surface TRPV5 after short (4-
hour) exposure of renal cortical epithelial cells from TRPV5-eGFP Tg mice to cytomix.
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Fig. 5. (A) Hypersialylation of renal TRPV5 in experimental colitis
TRPV5 was immunoprecipitated from control or TNBS-treated mice, and probed with
biotinylated lectin from Sambucus nigra. Detection with streptavidin-HRP conjugate (image
representative of n=3). (B) Recombinant soluble KLOTHO (20ng/ml) prevents TRPV5 loss
of surface expression in MDCK and mIMCD3 cells transduced with Ad-HA-TRPV5 and
treated with cytomix (images representative of three independent experiments). The bottom
panels depict densitometric quantification of TRPV5 protein levels. Data are expressed as %
change ± SD. *p < 0.05, compared to untreated cells. #p<0.05 compared to cytomix treated.
(C) TRPV5 expression in control and TNBS-treated wild-type and EFmKL46 transgenic
mice. Total TRPV5 expression in renal cortex with β-actin as loading control. (D) Renal
TRPV5 protein expression in CD4+CD45RBhi-T-Cell transfer model. Control (PBS-
injected) and T-cell transferred mice were injected i.p. with PBS or recombinant Klotho
(2μg/mouse) daily for 7 days starting 6-weeks post-transfer. (E) Densitometric
quantification of TRPV5 protein in CD4+CD45RBhi-T-Cell transfer model. Data
normalized to GAPDH. (F) The effects of recombinant Klotho injection on the fractional
urinary Ca2+ excretion (FECa2+) in CD4+CD45RBhi-T-Cell transfer model. Mean ± SD,
*p < 0.05, when compared to PBS injected, #p<0.05 compared to Klotho injected mice.
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Fig. 6. (A) Ubiquitination, cell surface expression, and degradation of TRPV5 in response to
cytomix in mIMCD3 and mKL-mIMCD3 cells
mIMCD3 or mKL-mIMCD3 cells were transduced with Ad-HA-TRPV5- and then treated
with control medium or medium supplemented with cytomix for 4 or 8 hours. Cell surface
proteins were biotinylated and pulled down with streptavidin beads, while TRPV5 was
immunoprecipitated with anti-HA antibody. Immunoprecipitates were probed with
antibodies against ubiquitin (Ub). Surface and total expression of TRPV5, total expression
of KLOTHO, and GAPDH (loading control) were analyzed by western blotting. (B)
Cytomix does not affect physical interactions of KLOTHO and TRPV5 in mKL-mIMCD3
cells. mKL-mIMCD3 cells were transduced with Ad-HA-TRPV5- and treated with control
medium or cytomix for 8 hours. TRPV5 or KLOTHO were immunoprecipitated with
respective epitope tag antibodies and the interacting counterpart detected by Western
blotting (image representative of three independent experiments).
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Fig. 7. UBR4/p600 ubiquitin ligase is responsible for TRPV5 ubiquitination and proteasomal
degradation in response to cytomix
(A) A typical MS/MS spectrum for one of the peptides identified from UBR4 protein is
shown with its corresponding b/y fragment ions used in determining the sequence. The high-
scoring peptides as described in Materials and Methods are listed in the table below. (B)
Decreased expression of UBR4 mRNA by qRT-PCR(left) and UBR4 protein (by dot blot;
right) in mIMCD3 cells transfected with UBR4 siRNA. (C) mIMCD3 cells were transduced
with Ad-HA-TRPV5, transfected with non-silencing or UBR4 siRNA, and treated with
Radhakrishnan et al. Page 18













control or cytomix medium. HA-TRPV5 was immunoprecipitated and probed for ubiquitin
(Ub) and pulled-down TRPV5; GAPDH was detected in total cell lysate as input control.
(D) Expression of total TRPV5 and GAPDH in Ad-HA-TRPV5-transduced mIMCD3 cells
transfected with respective siRNA and treated with control medium or cytomix. (E)
mIMCD3 cells stably transfected with GFP-TRPV5 were treated with control or cytomix
medium supplemented with DMSO or with proteosomal or lysosomal inhibitors, MG-132,
clasto-lactacystin β-lactone (CL-βL), and bafilomycin. Expression of total TRPV5 and
GAPDH was analyzed by Western blotting (all images representative of at least three
independent experiments). (F) Summary cartoon of the proposed mechanism responsible for
increased urinary Ca2+ loss during colitis.
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